178 related articles for article (PubMed ID: 29157102)
21. Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer.
Chung S; Vail P; Witkiewicz AK; Knudsen ES
Clin Cancer Res; 2019 Apr; 25(7):2290-2304. PubMed ID: 30538111
[TBL] [Abstract][Full Text] [Related]
22. Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924.
Liao H; Liu XJ; Blank JL; Bouck DC; Bernard H; Garcia K; Lightcap ES
Mol Cell Proteomics; 2011 Nov; 10(11):M111.009183. PubMed ID: 21873567
[TBL] [Abstract][Full Text] [Related]
23. Nedd8-activating enzyme inhibitor MLN4924 provides synergy with mitomycin C through interactions with ATR, BRCA1/BRCA2, and chromatin dynamics pathways.
Garcia K; Blank JL; Bouck DC; Liu XJ; Sappal DS; Hather G; Cosmopoulos K; Thomas MP; Kuranda M; Pickard MD; Liu R; Bandi S; Smith PG; Lightcap ES
Mol Cancer Ther; 2014 Jun; 13(6):1625-35. PubMed ID: 24672057
[TBL] [Abstract][Full Text] [Related]
24. MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studies.
Kuo KL; Ho IL; Shi CS; Wu JT; Lin WC; Tsai YC; Chang HC; Chou CT; Hsu CH; Hsieh JT; Chang SC; Pu YS; Huang KH
Cancer Lett; 2015 Jul; 363(2):127-36. PubMed ID: 25615422
[TBL] [Abstract][Full Text] [Related]
25. Quantifiable analysis of cellular pathway inhibition of a Nedd8-activating enzyme inhibitor, MLN4924, using AlphaScreen.
Yan ZH; Burkhardt A; Loke HK; Chen J; Xu Q; Brauer P; Ma J; Lin Y; Garcia K; Dick LR; Bembenek ME
Anal Biochem; 2013 Aug; 439(2):109-15. PubMed ID: 23624319
[TBL] [Abstract][Full Text] [Related]
26. Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo.
Montano R; Thompson R; Chung I; Hou H; Khan N; Eastman A
BMC Cancer; 2013 Dec; 13():604. PubMed ID: 24359526
[TBL] [Abstract][Full Text] [Related]
27. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.
Soucy TA; Smith PG; Milhollen MA; Berger AJ; Gavin JM; Adhikari S; Brownell JE; Burke KE; Cardin DP; Critchley S; Cullis CA; Doucette A; Garnsey JJ; Gaulin JL; Gershman RE; Lublinsky AR; McDonald A; Mizutani H; Narayanan U; Olhava EJ; Peluso S; Rezaei M; Sintchak MD; Talreja T; Thomas MP; Traore T; Vyskocil S; Weatherhead GS; Yu J; Zhang J; Dick LR; Claiborne CF; Rolfe M; Bolen JB; Langston SP
Nature; 2009 Apr; 458(7239):732-6. PubMed ID: 19360080
[TBL] [Abstract][Full Text] [Related]
28. MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy.
Nawrocki ST; Griffin P; Kelly KR; Carew JS
Expert Opin Investig Drugs; 2012 Oct; 21(10):1563-73. PubMed ID: 22799561
[TBL] [Abstract][Full Text] [Related]
29. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells.
Lin JJ; Milhollen MA; Smith PG; Narayanan U; Dutta A
Cancer Res; 2010 Dec; 70(24):10310-20. PubMed ID: 21159650
[TBL] [Abstract][Full Text] [Related]
30. SOMCL-19-133, a novel, selective, and orally available inhibitor of NEDD8-activating enzyme (NAE) for cancer therapy.
Zhou LN; Xiong C; Cheng YJ; Song SS; Bao XB; Huan XJ; Wang TY; Zhang A; Miao ZH; He JX
Neoplasia; 2022 Oct; 32():100823. PubMed ID: 35907292
[TBL] [Abstract][Full Text] [Related]
31. Radiosensitization of Human Colorectal Cancer Cells by MLN4924: An Inhibitor of NEDD8-Activating Enzyme.
Wan J; Zhu J; Li G; Zhang Z
Technol Cancer Res Treat; 2016 Aug; 15(4):527-34. PubMed ID: 26082455
[TBL] [Abstract][Full Text] [Related]
32. Gene expression profiling reveals the genomic changes caused by MLN4924 and the sensitizing effects of NAPEPLD knockdown in pancreatic cancer.
Li JA; Rong Y; Mao W; Zhang L; Kuang T; Lou W
Cell Cycle; 2022 Jan; 21(2):152-171. PubMed ID: 34874801
[TBL] [Abstract][Full Text] [Related]
33. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.
Milhollen MA; Traore T; Adams-Duffy J; Thomas MP; Berger AJ; Dang L; Dick LR; Garnsey JJ; Koenig E; Langston SP; Manfredi M; Narayanan U; Rolfe M; Staudt LM; Soucy TA; Yu J; Zhang J; Bolen JB; Smith PG
Blood; 2010 Sep; 116(9):1515-23. PubMed ID: 20525923
[TBL] [Abstract][Full Text] [Related]
34. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.
Carrassa L; Chilà R; Lupi M; Ricci F; Celenza C; Mazzoletti M; Broggini M; Damia G
Cell Cycle; 2012 Jul; 11(13):2507-17. PubMed ID: 22713237
[TBL] [Abstract][Full Text] [Related]
35. Promoting tumorigenesis in nasopharyngeal carcinoma, NEDD8 serves as a potential theranostic target.
Xie P; Yang JP; Cao Y; Peng LX; Zheng LS; Sun R; Meng DF; Wang MY; Mei Y; Qiang YY; Cao L; Xiang YQ; Luo DH; Yun JP; Huang BJ; Jia LJ; Qian CN
Cell Death Dis; 2017 Jun; 8(6):e2834. PubMed ID: 28569775
[TBL] [Abstract][Full Text] [Related]
36. The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth.
Luo Z; Yu G; Lee HW; Li L; Wang L; Yang D; Pan Y; Ding C; Qian J; Wu L; Chu Y; Yi J; Wang X; Sun Y; Jeong LS; Liu J; Jia L
Cancer Res; 2012 Jul; 72(13):3360-71. PubMed ID: 22562464
[TBL] [Abstract][Full Text] [Related]
37. Suppression of glioblastoma by targeting the overactivated protein neddylation pathway.
Hua W; Li C; Yang Z; Li L; Jiang Y; Yu G; Zhu W; Liu Z; Duan S; Chu Y; Yang M; Zhang Y; Mao Y; Jia L
Neuro Oncol; 2015 Oct; 17(10):1333-43. PubMed ID: 25904638
[TBL] [Abstract][Full Text] [Related]
38. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG
Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798
[TBL] [Abstract][Full Text] [Related]
39. The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine.
Nawrocki ST; Kelly KR; Smith PG; Keaton M; Carraway H; Sekeres MA; Maciejewski JP; Carew JS
Clin Cancer Res; 2015 Jan; 21(2):439-47. PubMed ID: 25388161
[TBL] [Abstract][Full Text] [Related]
40. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
Wong KM; Micel LN; Selby HM; Tan AC; Pitts TM; Bagby SM; Spreafico A; Klauck PJ; Blakemore SJ; Smith PF; McDonald A; Berger A; Tentler JJ; Eckhardt SG
Invest New Drugs; 2017 Feb; 35(1):11-25. PubMed ID: 27783255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
